KAYTUS
23.5.2024 17:14:31 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, unveiled the KR2280V2 2U, 2-socket flagship server at ISC High Performance 2024. This powerhouse server supports the 4th/5th Gen Intel® Xeon®, 4th Gen AMD EPYCTM, and AmpereOne® processors, offering an impressive array of storage combinations with up to 20 LFF drives, 45 SFF drives, or 24 E3.S SSDs. When upgraded with CXL modules, the KR2280V2 horizontally expands to 16 DIMMs, effortlessly meeting the demands of memory-intensive applications. Its innovative front I/O configuration delivers remarkable scalability, supporting up to 20 PCIe 5.0 devices, setting a new benchmark in performance. With its flexible compute capabilities and adaptable storage and I/O designs, the KR2280V2 is engineered to accommodate a wide spectrum of business needs— ranging from general computing to accelerated computing, and from massive storage capacity to high-performance I/O-oriented applications. This versatility makes it the ultimate solution for diverse application scenarios, ensuring consistent and efficient operation and maintenance.
Revolutionizing Diverse Applications Scenarios with Versatile Compute Power
To deliver the best computing solutions for diverse scenarios, the IT architecture of data centers is rapidly evolving and becoming increasingly sophisticated. As business needs diversify, a single chip can no longer meet the demands of complex, high-efficiency computing, leading to the emergence of various acceleration chips. This rapid evolution places new demands on processors' energy efficiency and core performance. The KR2280V2 boldly rises to this challenge by supporting three major computing platforms: Intel® Xeon®, AMD EPYC™, and AmpereOne®. This versatility offers a wide range of computing power options, perfectly tailored for different scenarios. By unifying management interfaces, the KR2280V2 dramatically reduces operation and maintenance pressure in heterogeneous computing configurations, making it exceptionally user-friendly and efficient.
Unparalleled Configuration Flexibility Optimized for Peak Application Performance
Through highly advanced modularization, KR2280V2 enables dynamic configurations of storage, I/O, and acceleration modules, offering an impressive array of over 100 configurations. This versatility seamlessly adapts to various scenarios, from general computing to cutting-edge heterogeneous computing, from storage-intensive to blazing-fast I/O-intensive applications, and from traditional rear I/O maintenance to innovative front I/O maintenance design. When it comes to energy efficiency, the KR2280V2 leads the way with its fully compatible cold-plated liquid cooling design, enhanced with state-of-the-art leakage detection mechanisms and bolstered system reliability.
Industry's First to Achieve BSI Cryptographic Uncompromising Security Encryption
The cryptographic module employed in KR2280V2's BMC out-of-band management module establishes a new security benchmark. It adheres fully to the stringent ISO/IEC 19790:2012 requirements, delivering excellence across role permissions, service and authentication, software/firmware security, operating environment security, and full-process self-inspection. Simultaneously, it ensures an end-to-end security system through the integration of state-of-the-art technologies. From dual flash chips to BMC self-recovery mechanisms, comprehensive access control, and multiple authentications, every aspect is meticulously designed to safeguard critical business data with uncompromising encryption. The KR2280V2 sets the standard for data security in the digital age.
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523414563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
